PMID- 20065633
OWN - NLM
STAT- MEDLINE
DCOM- 20100405
LR  - 20240314
IS  - 1942-0870 (Electronic)
IS  - 1942-0862 (Print)
IS  - 1942-0862 (Linking)
VI  - 1
IP  - 5
DP  - 2009 Sep-Oct
TI  - Tocilizumab.
PG  - 432-8
AB  - Roche is co-developing tocilizumab (Actemra, RoActemra), a humanized 
      anti-interleukin-6 receptor (IL-6R) monoclonal antibody, with Chugai 
      Pharmaceutical. Tocilizumab is marketed in Japan for Castleman disease and 
      several types of arthritis. The product is approved in the European Union for 
      treatment of moderate-to-severe rheumatoid arthritis, and is currently undergoing 
      review by the US Food and Drug Administration for this condition. Tocilizumab has 
      also been studied for potential use in the treatment of other IL-6 related 
      disorders including Crohn disease.
FAU - Venkiteshwaran, Adith
AU  - Venkiteshwaran A
AD  - Rensselaer Polytechnic Institute, Troy, NY, USA. sohini.mazumdar@tufts.edu
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20090910
PL  - United States
TA  - MAbs
JT  - mAbs
JID - 101479829
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Receptors, Interleukin-6)
RN  - I031V2H011 (tocilizumab)
SB  - IM
MH  - Animals
MH  - *Antibodies, Monoclonal/administration & dosage/adverse 
      effects/immunology/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Castleman Disease/*drug therapy
MH  - Clinical Trials as Topic
MH  - Crohn Disease/*drug therapy
MH  - Drug Administration Schedule
MH  - European Union
MH  - Humans
MH  - Japan
MH  - Mice
MH  - Receptors, Interleukin-6/*immunology
MH  - Treatment Outcome
MH  - United States
PMC - PMC2759492
EDAT- 2010/01/13 06:00
MHDA- 2010/04/07 06:00
PMCR- 2010/09/01
CRDT- 2010/01/13 06:00
PHST- 2010/01/13 06:00 [entrez]
PHST- 2010/01/13 06:00 [pubmed]
PHST- 2010/04/07 06:00 [medline]
PHST- 2010/09/01 00:00 [pmc-release]
AID - 9497 [pii]
AID - 1942-0862-1-5-5 [pii]
AID - 10.4161/mabs.1.5.9497 [doi]
PST - ppublish
SO  - MAbs. 2009 Sep-Oct;1(5):432-8. doi: 10.4161/mabs.1.5.9497. Epub 2009 Sep 10.